MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development

SIMPLE SUMMARY: Prostate cancer is still the most common cancer among men in the US. Current standard-of-care therapies for metastatic castration-resistant prostate cancer can offer survival benefits measured only in months. The patients eventually develop drug resistance and tumor relapse. There is...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wen (Jess), Liu, Xiaozhuo, Dougherty, Emily M., Tang, Dean G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497236/
https://www.ncbi.nlm.nih.gov/pubmed/36139695
http://dx.doi.org/10.3390/cancers14184538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497236/
https://www.ncbi.nlm.nih.gov/pubmed/36139695
http://dx.doi.org/10.3390/cancers14184538

Ejemplares similares